Lansoprazole

Research use only, not for human use.

Lansoprazole is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid.

Lansoprazole is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid.(In Vitro):Lansoprazole from 0.3 to 3 μM inhibits gastric acid formation in a concentration-dependent manner (IC50 of 0.76 μM).Lansoprazole (30-300 μM) both induced concentration-dependent, reversible and reproducible relaxations of arteries.(In Vivo):Lansoprazole (20-40 mg/kg) treatment significantly attenuated STZ and HFD -induced memory deficits, biochemical and histopathological alterations.Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced increase in AChE activity.Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced rise in brain MPO level.Further HFD mice treated with lansoprazole (20 mg/kg and 40 mg/kg, p.o.) shows a marked decrease in the body weight in comparison to the control animals.

——

Animal Model:Swiss albino mice (20–25 g) of either sex.Dosage:20 mg/kg, 40 mg/kg.Administration:PO, started after second dose of STZ and then subjected to MWM test. Continued (30 min before) during the acquisition trial conducted from day 1 to day 4. Result:Significantly attenuated the day 4 rise in ELT and decreased in day 5 TSTQ in the STZ as well as HFD treated mice in a dose dependent manner.

AG-1749

Membrane Transporter/Ion Channel

Proton Pump

Proton pump

Inflammation/Immunology

——

103577-45-3

369.36

C16H14F3N3O2S

>98% (HPLC)

Ethanol: 14 mg/mL (37.9 mM); DMSO: 74 mg/mL (200.34 mM)

O=S(C1=NC2=CC=CC=C2N1)CC3=NC=CC(OCC(F)(F)F)=C3C

2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole

(-20℃)

With Ice Pack

≥ 2 years